New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...
MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...
As the American Urological Association (AUA) annual meeting prepares to kick off on May 12, newly published prostate cancer guidelines recommend two tests to help clinicians and patients determine the ...
REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...
Please provide your email address to receive an email when new articles are posted on . Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx ...
The NCCN Clinical Practice Guidelines in Oncology cites the test as a recommendation to determine treatment for patients with ER-positive, HER2-negative tumors without axillary lymph node metastases.
First clinical validation of the Oncodetect ® test to be presented in triple negative breast cancer; signals highly sensitive molecular residual disease (MRD) detection The Oncotype DX ® test is ...